[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330050":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":34,"studyPopulation":35,"armGroups":30,"interventions":30,"overallOfficials":30,"centralContacts":36,"locations":45,"responsibleParty":60,"collaborators":64,"id":84,"slug":30,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":30,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":30,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Academisch Ziekenhuis Maastricht","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Treatment pattern","Treatment pattern per palliative treatment line; proportion of patients receiving chemotherapy, chemotherapy plus targeted therapy, endocrine therapy, endocrine therapy plus targeted therapy or targeted therapy alone","up to 13 years",[14,17,20,23,27],{"measure":15,"description":16,"timeFrame":12},"OS","Overall survival",{"measure":18,"description":19,"timeFrame":12},"PFS","Progression-free survival per systemic agent or palliative treatment line",{"measure":21,"description":22,"timeFrame":12},"ICER","Incremental cost-effectiveness ratio per QALY (quality-adjusted life year) gained of a new systemic drug compared with standard care",{"measure":24,"description":25,"timeFrame":26},"QoL","Quality of life; health state utility score calculated from the EQ-5D questionnaire","upt to 13 years",{"measure":28,"description":29,"timeFrame":12},"Costs","Costs of advanced breast cancer care from a hospital perspective",null,{"allocation":30,"interventionModel":30,"interventionModelDescription":30,"primaryPurpose":30,"observationalModel":32,"timePerspective":33,"maskingInfo":30},"COHORT","PROSPECTIVE","This SONABRE registry is an ongoing observational cohort study aiming at the inclusion of all patients aged ≥18 years and diagnosed with advanced breast cancer since 2007 in 11 hospitals in the Southeast of the Netherlands. Patients with de novo or recurrent advanced breast cancer were identified from the hospital-based management information systems. Specially trained registration clerks retrospectively collected data from the medical files of the patients based on extensive medical chart review. Information was collected about patient and tumour characteristics, type of treatment (surgery, radiotherapy and systemic treatment, both neo-adjuvant, adjuvant and palliative), palliative treatment changes due to adverse events, hospitalization, comorbidities and outcomes (progression and death). The SONABRE Registry has already been effectively used to perform real-life studies on the use, safety and (cost-)effectiveness of various systemic treatments used in patients diagnosed with advanced breast cancer.","All consecutive patient diagnosed with advanced breast cancer since 2007 in 11 hospitals in the Netherlands. No patients are being excluded. Also patients with no systemic \u002F active anti-tumour therapy for advanced breast cancer will be included. The SONABRE Registry includes 11 hospitals: 1 academic, 7 teaching and 3 general hospitals. The Netherlands counts 114 hospitals, including 8 academic, 25 teaching, 58 general and 23 categorical hospitals.",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},"Vivianne CG Tjan-Heijnen, MD, PhD","CONTACT","+31 (0) 43 3877025","vcg.tjan.heijnen@mumc.nl",{"name":43,"role":39,"phone":40,"phoneExt":30,"email":44},"Sandra ME Geurts, PhD","sandra.geurts@mumc.nl",[46],{"facility":47,"status":48,"city":49,"state":30,"zip":30,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Multiple hospitals in the Netherlands (see Eligibility)","RECRUITING","Maastricht","Netherlands","NL",{"type":53,"coordinates":54},"Point",[55,56],5.68889,50.84833,{"lat":56,"lon":55},[59],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","V.C.G. Tjan-Heijnen","Professor of medical oncology",[65,68,70,72,74,76,78,80,82],{"name":66,"class":67},"Novartis","INDUSTRY",{"name":69,"class":67},"Pfizer",{"name":71,"class":67},"Roche Pharma AG",{"name":73,"class":67},"Eli Lilly and Company",{"name":75,"class":6},"ZonMw: The Netherlands Organisation for Health Research and Development",{"name":77,"class":67},"Eisai Inc.",{"name":79,"class":67},"Daiichi Sankyo",{"name":81,"class":67},"AstraZeneca",{"name":83,"class":67},"Gilead Sciences","100330050",false,"NCT03577197","Southeast Netherlands Advanced Metastatic Breast Cancer Registry","Southeast Netherlands Advanced Breast Cancer Registry","SONABRE","Inclusion Criteria:\n\n* Diagnosed with de novo or recurrent advanced breast cancer since 2007\n* Diagnosed with or treated for advanced breast cancer in one of the participating hospitals\n* Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard\u002FHeerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven\u002FEindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo\u002FVenray (2013-2025), all in the Netherlands.\n* Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.\n* The inclusion period may be prolonged after 2025.\n\nExclusion Criteria: none","ALL","18 Years",{"count":94,"type":95},7000,"ESTIMATED","5 Years","OBSERVATIONAL","The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.",[100,101],"Advanced Breast Cancer","Metastatic Breast Cancer",[103,104,105],"Breast neoplasms","Neoplasm Metastasis","Registry","2024-07-19",{"date":108,"type":109},"2024-07-23","ACTUAL",{"date":111,"type":109},"2007-01-01",{"date":113,"type":95},"2027-12-31",{"name":5,"class":6},1]